Connect with us

BUSINESS

Abattis Bioceuticals Corp (OTCMKTS:ATTBF) Unveils “Comfort” A New Product Line Targeting Chronic Pain & Inflammation

Published

on

The pharmaceutical industry is set to receive a new boost; thanks to Abattis Bioceuticals Corp (OTCMKTS:ATTBF). The cannabis company well – known for its diversification says it is on the verge of releasing a new chronic pain and inflammation product. The launch of the product known as “Comfort” is as a result of an extensive research by the Cannabis solution provider.

Abattis has been holding onto this vision of enlarging its product line in an effort to propel its vision. This is the more reason it has invested heavily in research, partnerships and comparison studies. It is already working on a phase 1 study, targeting the exploration and the development of nanoemulsified and liposomal platforms. The study is in partnership with the University of British Columbia and Mitacs.

Comfort will address the needs of the severe disabling condition

Chronic pain and inflammation is a growing problem. Reports from the Industry of Medicine indicate that close to 100 million people in North America are at the mercy of this condition. The condition affects the internal systems of a person, which in return fail to produce the required endogenous chemicals. What follows is severe pain known to last for too long.

The report further explains how millions of people are not able to access the necessary medical treatments. They are either too expensive or are not available. This not only brings along lost productivity but in the very severe cases have resulted in death.

However, Abattis President and CEO, Rob Abenante cited, “With Comfort, we hope to address a severely disabling condition that affects a large proportion of our population.”

Abattis is confident about its Research and Development strategy

Apart from partnering with a number of corporations, Abattis is also seeking to obtain a Health Canada dealer’s license. If approved, the company will be able to trade in Cannabis flower and oils. It will also integrate into its business key acquisitions. The company is seriously engaged in growing of its retail distribution. It will leave nothing to chance when it comes to research and development.

Clearly, Abattis is establishing a footprint in the cannabis industry from its research and development work.

BUSINESS

Sundial Growers Inc (NASDAQ:SNDL) And Vir Biotechnology Inc (NASDAQ:VIR) Strike Deal To Support Clinical Studies

Published

on

Sundial Growers Inc (NASDAQ:SNDL) and Vir Biotechnology Inc (NASDAQ:VIR) are into a new deal that spans about three years. The terms of the deal outline that Sundial will be serving Vir Pharma with medical cannabis oil supplies.

The business cooperation

On the other hand, Vir Pharma intends to make an impact in the treatment of chronic pain and will be using products from the business partner. The plan is to conduct its clinical studies effectively in Australia, and the oral formulations will be used in the development of its prescription drug.

The proprietary drug will be developed using cannabis products, and the company is optimistic patients will benefit from the medication. It will be about giving them a break from the use of the various treatments developed using opioids.

Thoughts from leaders

The Chief Operating Officer of Sundial, known as Brian Harriman, is one of the leaders that have spoken concerning the matter. The official has termed the recent move an outstanding one considering that it is about them triumphant entry into Australia. It also marks the company’s first global exports, and the official believes that they are taking steps in the right direction.

The leader also thinks quite highly about their business partner calling it one of the leading companies in the market. He believes that it is such a great honor getting the opportunity to work with Vir Pharma on their quest to grasp business leadership. Harriman also says that the patients in Australia deserve the best form of treatment, and it is a good thing that they will be receiving the top quality cannabis-based therapies.

The terms of this deal also provide that the cannabis blend developed by the two will be marketed under Vir Pharma’s label, and the brand name will be Virabis.

The CEO of Vir Pharma Joel Hardy has also spoken on behalf of his company, outlining that they are proud to be a part of the companies focusing on developing cannabis medicines. According to him, these full-spectrum medicines are essential in helping to eliminate or minimize the use of opioid products as a form of treatment. He says that he will be at the frontline in supporting the cooperation between the two companies.

Continue Reading

BUSINESS

Amyris Inc (NASDAQ:AMRS) Completes The Shipment Of First Cannabinoids To LAVVAN: Gearing To Ship Second Cannabioid Shipment In H1 2020

Published

on

Amyris Inc (NASDAQ:AMRS) has completed the first shipment of cannabinoids to its associate – LAVVAN. The company is also gearing to meet the second shipment of cannabinoids in H1 2020. It has developed the ingredients using its fermentation technology platform. The company is maintaining high purity and quality when compared to the ingredients derived from cannabis plants.

A leader in natural ingredients

Amyris uses its proprietary technology to scale the ingredients.  The company is a leader in extracting the natural and clean beauty ingredients using fermentation. It also entered a pact with a leading pharmaceutical company in Asia to develop and target oncology treatment. Amyris also signed a pact with its partner in China for vitamins.

Committed to delivering the highest purity ingredients

Chief Executive Officer and President of Amyris, John Melo, said the company is pleased to close the year 2019 with significant progress in business and operational performance. The company expects to maintain its leadership by delivering the highest purity ingredients for beauty, health, fragrance, and flavor industries. Amyris expects to report a strong quarter by delivering leading products.

Amyris posted record production in Q4 2019; its clean beauty business is also delivering better than expected performance. The company is satisfying the strong consumer and market demand for natural and clean products. John said its team reported excellent production and shipment volumes. The team helped to deliver high-quality renewable products to the consumers.

Amyris started 2020 with excellent performance. It expects to double the sales this year, especially after posting better performance in Clean Beauty. The company already posted a 190% growth in the first 12 days of this month after reporting strong Biossance results in January 2019.

John further said the company benefitted from its technological advantage and reputation to scale up products and achieve commercial success. It formed a basis to apply for intellectual property and mobilize funds for the business. The company is celebrating the commercial success of its first cannabinoids.

Amyris introduces PURECANE Brand sweetener

Amyris has introduced PURECANE brand sweetener online for the consumer to make immediate purchases. It is great news for health-conscious consumers to enjoy sweet indulgences.

Continue Reading

BUSINESS

SinglePoint, Inc. (OTCMKTS:SING) Expects To Post Revenues Of Over $10 Million In 2020

Published

on

SinglePoint, Inc. (OTCMKTS:SING) expects to post revenues of more than $10 million in 2020, mainly from its subsidiary SinglePoint Direct Solar LLC. The company acquired a stake of 50% in Direct Solar in 2019. Greg Lambrecht, Chief Executive Officer of SinglePoint, expressed sincere thanks to over 24,000 shareholders for their continued support and helping the company to lay the foundation to post significant growth this year.

Deployed 60 people

Direct Solar has positioned more than 60 employees across twenty cities and eleven states. The company introduced its proprietary brand – 1606 Original Hemp in Q3 and Q4 of 2019. Direct Solar rolled out this product with 20% CBD and less than 0.3% THC (in each roll) to offer a smooth experience and a substitute to marijuana and tobacco products. It is 100% safe and tested for pesticides, mico toxins, microbials, and heavy metals. Several retail outlets and distributors have already picked up this product. The company has already received a purchase order for five thousand hemp cigarette packs. It expects to receive more purchase orders soon.

Gross revenues increases

SinglePoint expects to post revenues of $3 million in 2019 after witnessing a growth of 344% from 2018 to 2018. The company expects to post higher revenues this year because of Direct Solar contribution.

Outlook for 2020

SinglePoint will focus on high opportunity markets and improve revenues through strategic acquisitions. It will also develop talent in inhouse and in subsidiaries to drive growth going forward. The company established a scalable business model by taking over Direct Solar in mid-2019. It plans to expand the footprint across the nation through talented business professionals. Direct Solar expanded its business into several states that include Florida, South Carolina, Missouri, Florida, New Mexico, Texas, and Arizona.

Identifies contractors for a solar energy system

Direct Solar helps businesses to identify contractors to install the solar energy systems for commercial and residential locations. It ensures complete satisfaction and optimal savings for the customers. The customers can choose customized solutions for their energy needs by choosing from a variety of contractors.

SinglePoint’s investment in Jacksam Corporation is also yielding positive results. Its recently acquired Discount Indoor Garden Supplies, Inc is showing positive results.

Continue Reading



Trending Stories